Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitazalimab with mFOLFIRINOX in metastatic pancreatic cancer
NCT04888312Phase 2Active, not recruiting
- Sponsor
- Alligator Bioscience AB
- Start
- Sep 2021
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of mitazalimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Alligator Bioscience AB. Started Sep 2021; status: active, not recruiting.
02
Drugs
mitazalimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04888312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888312.